⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MDCX News
Medicus Pharma Ltd. Common Stock
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
globenewswire.com
MDCX
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
accessnewswire.com
MDCX
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
accessnewswire.com
MDCX
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
globenewswire.com
MDCX
New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST
accessnewswire.com
SAGT
MDCX
YYGH
NRXP
SNYR
SDST
DVLT
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
accessnewswire.com
MDCX
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
globenewswire.com
MDCX
New to The Street Broadcasts Tonight on Bloomberg Television at 6:30 PM EST - Shows 736, 737 and 738 Air Across the U.S., Latin America and MENA
accessnewswire.com
YYGH
SAGT
MDCX
VTIX
NRXP
SNYR
Form 8-K
sec.gov
MDCX
MDCXW
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
globenewswire.com
MDCX